Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO

Renaissance Capital2021-12-25

TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday. The Holytown, UK-based company now...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

etan000
2021-12-26
etan000
Ok
SeanSak
2021-12-26
SeanSak
Like n comment
sfleong1
2021-12-26
sfleong1
Like n comment
KeeBoonTong
2021-12-26
KeeBoonTong
Lalala
- KeeBoonTong:
  lalala
Zivcheah
2021-12-26
Zivcheah
O
- Zivcheah:
  O
matcha_latte
2021-12-26
matcha_latte
Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1130212885?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-25 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130212885","market":"us","top_or_hot":-1,"title":"Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO","media":"Renaissance Capital","content":"<div>\n<p>TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday.\nThe Holytown, UK-based company now...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89799/Scottish-biotech-TC-BioPharm-lowers-deal-size-by-40-adds-warrants-ahead-of-\">网页链接</a>\n\n</div>\n","source":"lsy1603787993745","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/89799/Scottish-biotech-TC-BioPharm-lowers-deal-size-by-40-adds-warrants-ahead-of-><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday.\nThe Holytown, UK-based company now...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89799/Scottish-biotech-TC-BioPharm-lowers-deal-size-by-40-adds-warrants-ahead-of-\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89799/Scottish-biotech-TC-BioPharm-lowers-deal-size-by-40-adds-warrants-ahead-of-","article_id":"1130212885","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130212885","pubTimestamp":1640397757,"sourceInfo":{"source_id":"lsy1603787993745","name":"Renaissance Capital"},"weMediaInfo":null,"summary":"TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies,","collect":0,"end_time":0,"defaultTopTitle":"renaissancecapital.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"苏格兰生物技术公司TC BioPharm将交易规模下调40%，在美国3000万美元IPO前增加认股权证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday.\nThe Holytown, UK-based company now plans to raise $30 million by offering 3.8 million ADSs at $8. The company is also offering 3.8 million warrants to purchase ADSs at $8, each with an exercise price of $10. The company had previously filed to offer 6.3 million shares at a range of $7 to $9. At the revised price, TC BioPharm Holdings will raise -40% less in proceeds than previously anticipated.Because the company is now offering warrants, TC BioPharm is no longer eligible for tracking and will be excluded from Renaissance Capital's stats.\nTC BioPharm (TCB) is focused on developing novel immunotherapies based on its proprietary allogeneic gamma-delta T cell (GD-T) platform. The company's Omnimmune program is expected to enter Phase 2-into-pivotal (Phase 3) trials in the 4Q21 for the treatment of acute myeloid leukemia (AML). The company plans to conduct similar trials for AML in the US following an application to the FDA in the 1H22. TCB is also developing a GD-T therapy for the treatment of COVID-19, with trials expected to start in the 4Q21, and genetically modified CAR-T therapies for solid cancers.\nTC BioPharm Holdings was founded in 2013 and booked $3 million in revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq under the symbol TCBP. EF Hutton is the sole bookrunner on the deal.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":698572284,"gmtCreate":1640482259882,"gmtModify":1640482260192,"author":{"id":"3582010497192751","authorId":"3582010497192751","name":"etan000","avatar":"https://static.tigerbbs.com/3cf965ffd3853f655731971c5c39433f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582010497192751","authorIdStr":"3582010497192751"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698572284","repostId":1130212885,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":698558728,"gmtCreate":1640476958576,"gmtModify":1640476959208,"author":{"id":"3581585664475701","authorId":"3581585664475701","name":"SeanSak","avatar":"https://static.tigerbbs.com/4a62d3d455150e01d4dc6c67bd4f9c0d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581585664475701","authorIdStr":"3581585664475701"},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698558728","repostId":1130212885,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":698553634,"gmtCreate":1640476244231,"gmtModify":1640476244915,"author":{"id":"3583570345500843","authorId":"3583570345500843","name":"sfleong1","avatar":"https://static.tigerbbs.com/2ec42f3f2b911279950a45a9140bc358","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583570345500843","authorIdStr":"3583570345500843"},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698553634","repostId":1130212885,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":698550209,"gmtCreate":1640475787754,"gmtModify":1640475788218,"author":{"id":"3578717603960999","authorId":"3578717603960999","name":"KeeBoonTong","avatar":"https://static.tigerbbs.com/815864515bc02d554ba00b04f5f46a1a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3578717603960999","authorIdStr":"3578717603960999"},"htmlText":"Lalala","listText":"Lalala","text":"Lalala","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698550209","repostId":1130212885,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7107683,"gmtCreate":1640475792620,"gmtModify":1640475792697,"authorId":3578717603960999,"author":{"id":3578717603960999,"idStr":"3578717603960999","authorId":3578717603960999,"name":"KeeBoonTong","avatar":"https://static.tigerbbs.com/815864515bc02d554ba00b04f5f46a1a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698550209,"type":1,"supId":0,"prevId":0,"content":"<u>lalala</u>","text":"<u>lalala</u>","html":"<u>lalala</u>"}],"langContent":"CN"},{"id":698567514,"gmtCreate":1640471523473,"gmtModify":1640471523580,"author":{"id":"3582538202393061","authorId":"3582538202393061","name":"Zivcheah","avatar":"https://static.tigerbbs.com/d52882be9b594ebb5b5933851792d286","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582538202393061","authorIdStr":"3582538202393061"},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698567514","repostId":1130212885,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7107308,"gmtCreate":1640471531115,"gmtModify":1640471531143,"authorId":3582538202393061,"author":{"id":3582538202393061,"idStr":"3582538202393061","authorId":3582538202393061,"name":"Zivcheah","avatar":"https://static.tigerbbs.com/d52882be9b594ebb5b5933851792d286","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698567514,"type":1,"supId":0,"prevId":0,"content":"O","text":"O","html":"O"}],"langContent":"CN"},{"id":698567363,"gmtCreate":1640470790551,"gmtModify":1640470790971,"author":{"id":"3581766638376505","authorId":"3581766638376505","name":"matcha_latte","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581766638376505","authorIdStr":"3581766638376505"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698567363","repostId":1130212885,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":93,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130212885"}